Literature DB >> 21157622

Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS.

Andreas Thomas1, Maxie Kohler, Wilhelm Schänzer, Philippe Delahaut, Mario Thevis.   

Abstract

Peptide analysis in doping controls by means of nano-UPLC coupled high resolution/high mass accuracy mass spectrometry provides the state-of-the-art technique in modern sports drug testing. The present study describes a recent application of this technique for the qualitative determination of different urinary insulin-like growth factor (IGF) related peptides. After simultaneous isolation by solid phase extraction and magnetic particle-based immunoaffinity purification, target analytes (IGF-1, IGF-2, Des1-3-IGF-1, R(3)-IGF-1 and longR(3)-IGF-1) were separated by nano-liquid chromatography prior to mass spectrometric detection. Endogenously produced IGF-1 and IGF-2, as well as the degradation product Des1-3-IGF-1, were frequently detected in urine samples from healthy volunteers in a concentration range of 20-400 pg mL(-1). The impact of IGF binding proteins (IGFBPs), being also present in urine, was potentially estimated by an additional ultrafiltration step in the sample preparation procedure. The synthetic analogue longR(3)-IGF-1, which is assumed to be subject to misuse by cheating athletes, was also analysed and detected in fortified urine samples. Besides the intact molecule, an N-terminally truncated degradation product Des1-10-longR(3)-IGF-1 was identified as the more stable target for doping controls using urine samples. The method was validated for qualitative purposes considering the parameters specificity, limit of detection (20-50 pg mL(-1)), recovery (10-35%), precision (<20%), linearity, robustness and stability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21157622     DOI: 10.1039/c0an00632g

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  7 in total

Review 1.  Hormones as doping in sports.

Authors:  Leonidas H Duntas; Vera Popovic
Journal:  Endocrine       Date:  2012-09-19       Impact factor: 3.633

2.  Doping in Two Elite Athletics Competitions Assessed by Randomized-Response Surveys.

Authors:  Rolf Ulrich; Harrison G Pope; Léa Cléret; Andrea Petróczi; Tamás Nepusz; Jay Schaffer; Gen Kanayama; R Dawn Comstock; Perikles Simon
Journal:  Sports Med       Date:  2018-01       Impact factor: 11.136

3.  Quantitation of endogenous GnRH by validated nano-HPLC-HRMS method: a pilot study on ewe plasma.

Authors:  Federica Dal Bello; Claudio Medana; Enrica Mecarelli; Riccardo Aigotti; Alberto Asteggiano; Paolo Giacobini; Manon Chasles; Yves Tillet
Journal:  Anal Bioanal Chem       Date:  2022-09-05       Impact factor: 4.478

4.  Quantitative and Selective Analysis of Feline Growth Related Proteins Using Parallel Reaction Monitoring High Resolution Mass Spectrometry.

Authors:  Mårten Sundberg; Emma M Strage; Jonas Bergquist; Bodil S Holst; Margareta Ramström
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators.

Authors:  Frank Klont; Nick H T Ten Hacken; Péter Horvatovich; Stephan J L Bakker; Rainer Bischoff
Journal:  Anal Chem       Date:  2017-05-10       Impact factor: 6.986

6.  Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry.

Authors:  Sophia Krombholz; Andreas Thomas; Mario Thevis
Journal:  Metabolites       Date:  2022-02-04

7.  Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1.

Authors:  Eric E Niederkofler; David A Phillips; Bryan Krastins; Vathany Kulasingam; Urban A Kiernan; Kemmons A Tubbs; Scott M Peterman; Amol Prakash; Eleftherios P Diamandis; Mary F Lopez; Dobrin Nedelkov
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.